Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Faculty debate the definitions of chemotherapy resistance, sensitivity, and refractoriness and discussed appropriate management strategies based on how patients would be classified in DLBCL.

Recent trials of novel therapies and therapeutic combinations have introduced promising options for the management of patients with relapsed or refractory diffuse large B-cell lymphoma.

Brad S. Kahl, MD, discusses the utility of tafasitamab combined with lenalidomide in patients with diffuse large B-cell lymphoma who are ineligible for CAR T-cell therapy.

Haifaa Abdulhaq, MD, discusses the benefits of chemotherapy-free options in diffuse large B-cell lymphoma.

Ian W. Flinn, MD, PhD, discusses the opportunity for second-line tafasitamab (MOR208, formerly Xmab®5574) as a palliative treatment of patients with diffuse large B-cell lymphoma.

Haifaa Abdulhaq, MD, discusses the safety profile of tafasitamab (MOR208) in diffuse large B-cell lymphoma.

Brad S. Kahl, MD, discusses findings from the phase 2 L-MIND study in diffuse large B-cell lymphoma.

Ian W. Flinn, MD, PhD, discusses the utility of tafasitamab (MOR208) in patients with relapsed diffuse large B-cell lymphoma (DLBCL).